Skip to main content

Top Left Menu

  • Careers
  • Media
  • Investors
  • Library

What are you looking for?

Home

You are here

Galderma Global

Choose another location

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong/Macau SAR, China
  • India
  • Italy
  • Japan
  • Kingdom of Saudi Arabia
  • Korea
  • Mainland China
  • Mexico
  • Middle East
  • Netherlands
  • Nordic
  • Norway
  • Poland
  • Portugal
  • Russia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, China
  • Thailand
  • United Kingdom
  • United States
  • Venezuela

Top menu

  • Contact us
  • Search

Main navigation

  • About us
    • At a glance
    • Our purpose
    • Our strategy
    • Our sub-categories
    • Global presence
    • Executive Committee
    • Governance
    • Annual Report 2025
  • Skin Stories
    • Galderma skin stories
    • Skin Science
    • Beauty x Medicine
    • Galderma Insights
    • Podcasts
  • Innovation
    • Bringing innovation to life
    • Partnerships
    • Manufacturing
    • Early Access
  • Our brands
  • Sustainability
    • For our employees
    • For patients and consumers
    • For healthcare professionals and customers
    • Governance oversight
    • Funding request for education and support activities
    • Our ESG Index
  • Media
  • Careers
  • Investors
You searched for: «【✈️ Telegram ID: KPU77】 대성피 성인 피시방 안전 보장 100% 알거래 중개소 리스트 - 용인»
Results 41 - 45 of 155
Page 9 of 31
  1. Media
  2. Newsroom

Nestlé Skin Health Honored by the American Federation for Aging Research

Nestlé Skin Health was honored with the 2016 Honorary Leadership Award from the American Federation for Aging Research (AFAR) for its Nestlé Skin Health SHIELD initiative (Skin Health Investigation, Education and Longevity Development) which aims to advance the future of skin health. AFAR is a U.S.

  1. Media
  2. Newsroom

ASDS 2025: Galderma’s scientific presentations

Galderma will present new data from its Injectable Aesthetics portfolio and pipeline at the American Society for Dermatologic Surgery (ASDS) 2025 Annual Meeting, held in Chicago from November 13-16. 

 

  1. Media
  2. Newsroom

Galderma demonstrates Injectable Aesthetics leadership in medication-driven weight loss with new research and first international consensus-based guidelines

  • New research shows that loose or sagging skin on the face and neck is most often noted after medication-driven weight loss, with facial changes typically observed 3-6 months following treatment (in 45% of respondents), and sometimes as early as 1-2 months (28%)[1]
  • In addition, more than 60% of those patients experiencing medication-driven weight
  1. Media
  2. Newsroom

Collaboration between Janssen’s and Galderma’s Nordic affiliates

Solna, April 23rd 2018 - Today the Nordic affiliates of Janssen and Galderma announced their long-term partnership for the marketing of TREMFYA® (guselkumab) for the treatment of moderate to severe plaque psoriasis.

  1. Media
  2. Newsroom

Galderma´s Azzalure and Dysport® celebrate a decade of treatment of the glabellar lines

For distribution outside the U.S. only

Azzalure also marketed as Dysport outside of the EU for the treatment of glabellar lines marks 10 year anniversary with more than 40 million treatments in the EU and US combined and approval in 72 countries.

 

Results 41 - 45 of 155
Page 9 of 31

Pagination

  • Previous page Previous Page
  • Next page Next Page
  1. Home
  2. Search results

STAY CONNECTED

Follow us on Social Media for current news and patients stories

Instagram LinkedIn Icon Twitter Icon
© Galderma 2026

Footer menu 2

  • Terms of use
  • Cookie Policy
  • Privacy
  • Sitemap

Confirm navigation

You are about to leave the Galderma global site. Are you sure you want to leave this page?

Yes, thanks Go back